Date: 2016-08-31
Type of information: Production agreement
Compound: Asacol™ (mesalamine), Entocort™ (budesonide)
Company: Recipharm (Sweden) Tillotts Pharma (Switzerland), part of Zeria group (Japan)
Therapeutic area:
Type agreement: production manufacturing supply
Action mechanism: glucocorticosteroid/antiinflammatory agent. Entocort™ is a locally-acting glucocorticosteroid currently approved in more than 40 countries as a first-line treatment for Crohn’s disease (CD) and, in some markets, ulcerative colitis (UC).
Disease: Crohn disease, ulcerative colitis
Details: * On August 31, 2016, Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with Tillotts Pharma. The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol. The partnership will also involve the commercial scale development of Tillotts’ ongoing development programme for TP05. All products are part of Tillotts’ dedication to innovative pharmaceutical products in the field of gastroenterology. Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac, France, tablet and capsule manufacturing including final packaging from its facility in Fontaine, France, and bottle filling from its site in Lisbon, Portugal. The total shared investment across the Recipharm network to enable this business amounts to €3.5 million. This includes investments to create new capacity as well as product specific investments. The collaboration between Recipharm and Tillotts Pharma marks an important step in Recipharm’s full service offering strategy, allowing customers to fulfil their needs for different technologies while working with Recipharm as one full service partner. This approach allows the CDMO to simplify both the technology transfer and scale-up of projects, as well as ongoing commercial supply.
Financial terms:
Latest news:
